Maternal Serum Screen, Alpha Fetoprotein
Also known as: MS AFP
Use
The Maternal Serum Screen, Alpha Fetoprotein (MS AFP) is a second-trimester screening test used to assess the risk of open neural tube defects, such as spina bifida, in the fetus. It is recommended for pregnant female patients during the specified gestational period. This test provides critical information to guide further diagnostic procedures and ensure proper prenatal care for patients at risk.
Special Instructions
Patient must provide detailed information including date of birth, current weight, due date, dating method, number of fetuses, race, diabetes status, smoking status, and medication use. Specimens should be accompanied by the Maternal Serum Testing Patient History Form.
Limitations
This screening cannot confirm open neural tube defects on its own. Factors such as gestational age accuracy, multiple gestations, ventral wall defects, or fetal demise might influence results. Genetic counseling and further diagnostic imaging or procedures (like amniocentesis) may be necessary to confirm findings and provide appropriate patient guidance.
New York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 1834-1
- 11778-8
- 20450-3
- 49586-1
- 19151-0
- 21299-3
- 44877-9
- 8670-2
- 21484-1
- 11878-6
- 21612-7
- 64234-8
- 18185-9
- 29463-7
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Serum Separator Tube (SST) or Plain Red.
Collection Instructions
Specimen must be drawn between 14 weeks, 0 days and 24 weeks, 6 days gestation. Separate from cells as soon as possible or within 2 hours of collection.
Storage Instructions
Refrigerated
Causes for Rejection
Plasma, hemolyzed specimens
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 72 hours |
| Refrigerated | 2 weeks |
| Frozen | 1 year (Avoid repeated freeze/thaw cycles.) |
Other tests from different labs that may be relevant